190 related articles for article (PubMed ID: 17203230)
1. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
Avnet S; Cenni E; Perut F; Granchi D; Brandi ML; Giunti A; Baldini N
Int J Oncol; 2007 Feb; 30(2):469-76. PubMed ID: 17203230
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor.
Morais C; Gobe G; Johnson DW; Healy H
Angiogenesis; 2009; 12(4):365-79. PubMed ID: 19882112
[TBL] [Abstract][Full Text] [Related]
3. Macrophage inflammatory protein-1 delta: a novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis.
Kominsky SL; Abdelmagid SM; Doucet M; Brady K; Weber KL
Cancer Res; 2008 Mar; 68(5):1261-6. PubMed ID: 18316587
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
Knowles HJ; Athanasou NA
J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
[TBL] [Abstract][Full Text] [Related]
5. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
6. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma.
Cenni E; Perut F; Granchi D; Avnet S; Amato I; Brandi ML; Giunti A; Baldini N
Anticancer Res; 2007; 27(1A):315-9. PubMed ID: 17352248
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiogenic activity of renal carcinoma by an antisense oligonucleotide targeting fibroblast growth factor-2.
Cenni E; Perut F; Zuntini M; Granchi D; Amato I; Avnet S; Brandi ML; Giunti A; Baldini N
Anticancer Res; 2005; 25(2A):1109-13. PubMed ID: 15868953
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
Thejass P; Kuttan G
Integr Cancer Ther; 2007 Dec; 6(4):389-99. PubMed ID: 18048887
[TBL] [Abstract][Full Text] [Related]
11. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
[TBL] [Abstract][Full Text] [Related]
12. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Rini BI; Rathmell WK
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):741s-746s. PubMed ID: 17255303
[TBL] [Abstract][Full Text] [Related]
13. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
14. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
15. Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis.
Shailubhai K; Dheer S; Picker D; Kaur G; Sausville EA; Jacob GS
J Exp Ther Oncol; 2004 Dec; 4(4):267-79. PubMed ID: 15844657
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
17. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer.
Rennel E; Mellberg S; Dimberg A; Petersson L; Botling J; Ameur A; Westholm JO; Komorowski J; Lassalle P; Cross MJ; Gerwins P
Exp Cell Res; 2007 Apr; 313(7):1285-94. PubMed ID: 17362927
[TBL] [Abstract][Full Text] [Related]
18. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
[TBL] [Abstract][Full Text] [Related]
19. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
Kurabayashi A; Inoue K; Fukuhara H; Karashima T; Fukata S; Kawada C; Shuin T; Furihata M
Cancer Sci; 2015 Aug; 106(8):1092-9. PubMed ID: 26041278
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha.
Miyake K; Tsuchida K; Sugino H; Imura S; Morine Y; Fujii M; Shimada M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):113-26. PubMed ID: 16699793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]